Last mentioned: 2d ago
Impurity Discovery
Lilly announces discovery of impurities in compounded samples and issues safety warnings.
Shortage Resolution
Expected timeframe for tirzepatide to be removed from FDA shortage list, ending legal compounding.
Impurity Warning
Lilly issues formal warning after testing reveals bacterial contamination in compounded samples.
Shortage Surge
Widespread shortages lead to a massive increase in compounding pharmacy production.
Initial Lawsuits
Lilly begins filing legal actions against medspas for trademark infringement.
Zepbound Approval
FDA approves Zepbound for chronic weight management.
Shortage Begins
FDA adds tirzepatide to the official drug shortage list, enabling compounding.
Mounjaro Approval
FDA approves Mounjaro for Type 2 diabetes treatment.
Eli Lilly has issued a formal warning regarding the discovery of impurities in compounded versions of its popular weight-loss treatments. The pharmaceutical giant highlighted significant safety risks associated with these unapproved alternatives, which have proliferated during ongoing supply shortages.
Eli Lilly has issued a formal warning after discovering impurities in compounded versions of its blockbuster weight-loss medication. The pharmaceutical giant cautioned that these unapproved formulations pose significant health risks to patients seeking alternatives during supply shortages.
Eli Lilly and Veeva Systems emerge as dominant healthcare growth leaders for 2026, driven by the GLP-1 weight-loss revolution and cloud-based life sciences infrastructure. Meanwhile, SoundHound AI is positioning itself to disrupt medical administrative costs through generative voice AI and automated customer service solutions.